GigaGen has relocated laboratory and office space in San Francisco to boost development of antibody therapeutics for patients with immune dysregulation.
Synpromics will make synthetic promotors for a collaboration with UCL Great Ormond Street Institute of Child Health to develop gene therapies for blood-based disorders.
The need for CDMOs with commercial gene therapy capacity is growing says Fujilfilm Diosynth Biotechnologies, which has opened an 80,000 square-foot plant in Texas.
Clover Biopharmaceuticals will adopt GE Healthcare’s centrally automated FlexFactory platform at its facility in Zhejiang, China where it plans to make a biosimilar to Amgen’s Enbrel.
ABL Europe will provide development, manufacturing and quality control release testing services for SillaJen’s oncolytic virus candidate JX-970 at its facility in Strasbourg.
The CDMO says it is building a 150,000 square-foot biomanufacturing facility in Maryland in preparation for a double-digit growth in the gene therapy space.
Celgene will add chimeric antigen receptor (CAR) and T-cell receptor (TCR) technologies through the acquisition of its immune-oncology partner Juno Therapeutics.
Cellular Biomedicine Group Inc (CBMG) has selected GE Healthcare’s FlexFactory technology for its CAR-T therapy production facility in Shanghai, China.
Novartis will install Berkeley Lights’ Beacon antibody discovery technology, the sixth large pharmaceutical firm to adopt the platform in less than a year.
Vector-based vaccine tech firm Vaccitech has secured £20m ($27.1m) in venture capital with investors Google Ventures, Sequoia China, Neptune Ventures and Oxford Sciences Innovation.
Celltrion has shelved plans for a third biomanufacturing plant at its site in Incheon in favour of an overseas site it says will help ensure biosimilar supply.
CAR T-cell understanding must come before the process design if such therapies are ever going to be accessible to a larger patient population, says Autolus.
Venture capital company Dynamk Capital has invested in FloDesign Sonics citing its acoustic wave separation technology’s application in the growing CAR T cell sector.
BeiGene’s tislelizumab will be the first commercial product to be made from Boehringer-Ingelheim’s site in Shanghai, and the first to be made by a foreign CMO in China.
Wacker Biotech will make the drug substance for Retavase (reteplase) at its German facility after completing a tech transfer from the recombinant enzyme’s original manufacturer Roche.
Abzena Plc has begun consolidating its UK operations at a facility in Cambridge and leased a plant in San Diego, US to consolidate its West Coast production activities.
Recent acquisitions CMC Biologics and Biomeva have been brought together under the single AGC Biologics brand in efforts to consolidate its CDMO business.
Takeda has said it will review the manufacturing of Alofisel (darvadstrocel) if its €520m ($620m) bid for off-the-shelf stem cell developer TiGenix is successful.
Novo Nordisk has called on the board of directors at Ablynx to engage in negotiations after the antibody-fragment tech firm rejected its €2.6bn ($3.1bn) acquisition offer.
Drug firms that want to trial or sell vaccines in India, or import them into the country, will need to seek CDSCO permission via an online portal from now on.